Answers are grounded in this paper and cite their sources.
Background: The severe coronavirus disease 2019 (COVID-19) induces widespread inflammatory responses that are attempted to be managed by the administration of anti-inflammatory drugs, along with antiviral drugs and respiratory support. This clinical trial study investigated the effect of short-term and low-dose methylprednisolone on the clinical outcome and radiological improvement of admitted patients with severe COVID-19. Methods: In this randomized clinical trial, two strains of patients with severe pneumonia of COVID-19 were evaluated before and after the use of corticosteroids. Inclusion criteria were age over 18 years, definitive case of COVID-19 based on positive reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), and arterial oxygen saturation (SaO2 )<93%; furthermore, at least 7 days and 5 days should be passed since the onset of symptoms and antiviral treatment, respectively. Exclusion criteria were similar to contraindications to the administration of methylprednisolone for short-term injections and pregnancy. Patients received intravenous methylprednisolone succinate (1-1.75 mg/kg/day) for 5 days in addition to treatment based on the World Health Organization (WHO) approved protocol for COVID-19. Finally, demographic characteristics, dyspnea, peripheral oxygen saturation (SpO2), number of lymphocytes, and computed tomography (CT) scan of the patient’s chest before and after taking corticosteroids were evaluated. Results: The average oxygen saturation of patients increased significantly after taking methylprednisolone succinate (P<0.001). Moreover, dyspnea and pulmonary insufficiency in CT scans improved significantly (P<0.001), and among hematological parameters, only lymphocytes increased significantly (P=0.01). Furthermore, methylprednisolone succinate use had no effect on mortality and length of hospitalization. Conclusion: Methylprednisolone succinate use during the treatment period of COVID-19 improves clinical conditions, CT scan findings, and hematological parameters affected by inflammation, but it does not affect the mortality and length of hospitalization of patients.
No takes yet. Share an insight, caveat, or question.
Mirenayat et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: